Background: Pneumonia stands as a widely known contributor to hospitalization and mortality among adults in the United States. Meanwhile, disruptions in potassium homeostasis such as hyperkalemia may have an impact on in-patient mortality. This study seeks to examine the presence of hyperkalemia and its association with in-patient mortality among pneumonia patients.

Methods: Electronic medical records were used to perform a retrospective observational cohort study in Southwest Missouri patients admitted to the hospital with pneumonia and/or hyperkalemia. Patients were divided into three samples: patients with pneumonia and hyperkalemia (P1), pneumonia without hyperkalemia (P2), and hyperkalemia without pneumonia (P3). The goal was to determine and compare the in-patient mortality rates of these samples.

Results: Patients with both pneumonia and hyperkalemia (P1) demonstrated the highest mortality rate, ranging from 34.25% to 42.31%, significantly surpassing rates observed in patients with pneumonia without hyperkalemia (P2) or hyperkalemia without pneumonia (P3). Notably, patients with pneumonia without hyperkalemia (P2) exhibited a mortality rate comparable to patients with hyperkalemia without pneumonia (P3).

Conclusion: Our study revealed that patients admitted to the hospital with pneumonia and hyperkalemia had a statistically significant increase in mortality in comparison to patients with pneumonia or hyperkalemia independently. Recognizing this association may help identify prognosis and thus guide the management of patients admitted to the hospital with both hyperkalemia and pneumonia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888787PMC
http://dx.doi.org/10.7759/cureus.78565DOI Listing

Publication Analysis

Top Keywords

pneumonia hyperkalemia
28
hyperkalemia pneumonia
24
patients pneumonia
20
hyperkalemia
15
pneumonia
14
in-patient mortality
12
patients admitted
12
admitted hospital
12
patients
10
mortality
8

Similar Publications

Objective: Predicting the occurrence of hyperkalemia in patients undergoing co-trimoxazole treatment for Pneumocystis pneumonia is critical. However, other factors besides drug exposure affect serum potassium levels, and various interventions are often used to treat hyperkalemia in clinical practice. Therefore, we aimed to develop a Markov model to predict the risk of hyperkalemia under various intervention conditions.

View Article and Find Full Text PDF

Background: Pneumonia stands as a widely known contributor to hospitalization and mortality among adults in the United States. Meanwhile, disruptions in potassium homeostasis such as hyperkalemia may have an impact on in-patient mortality. This study seeks to examine the presence of hyperkalemia and its association with in-patient mortality among pneumonia patients.

View Article and Find Full Text PDF

To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam-durlobactam. Sulbactam-durlobactam is a recently approved antimicrobial combination of two -lactamase inhibitors for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) associated with -calcoaceticus complex (ABC) in patients 18 years and older. Sulbactam is a direct antibacterial activity with high susceptibility to species.

View Article and Find Full Text PDF

Objective: To compare the rate of clinical cure and adverse effects in patients receiving definitive treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy for Stenotrophomonas maltophilia pneumonia.

Methods: A single-centre, retrospective cohort study of patients with S. maltophilia pneumonia admitted 1 March 2018-30 September 2023 was conducted comparing treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy.

View Article and Find Full Text PDF

A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis.

Front Endocrinol (Lausanne)

January 2025

Department of Nephrology, Affiliated Bao'an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, China.

Objectives: The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).

Methods: Various databases including PubMed, Sinomed, Web of Science, Embase, Clinical Trials, and Cochrane Library were systematically reviewed for pertinent studies published from the beginning to February 2024.This meta-analysis utilized RevMan 5.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!